AUTL logo

AUTL
Autolus Therapeutics Ltd - ADR

3,590
Mkt Cap
$377.92M
Volume
3,411.00
52W High
$2.70
52W Low
$1.11
PE Ratio
-1.68
AUTL Fundamentals
Price
$1.46
Prev Close
$1.42
Open
$1.42
50D MA
$1.56
Beta
1.26
Avg. Volume
2.35M
EPS (Annual)
-$0.8652
P/B
1.90
Rev/Employee
$15,648.00
Loading...
Loading...
News
all
press releases
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Hold" by Brokerages
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has been given an average recommendation of "Hold" by the six brokerages that are presently covering the stock, Marketbeat...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
New Strong Sell Stocks for January 30th
TSE, PAC and AUTL have been added to the Zacks Rank #5 (Strong Sell) List on January 30th, 2026.
Zacks·11d ago
News Placeholder
New Strong Sell Stocks for January 22nd
MHVYF, NFG and AUTL have been added to the Zacks Rank #5 (Strong Sell) List on January 22, 2026.
Zacks·19d ago
News Placeholder
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Moderate Buy" by Brokerages
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has received a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the stock, MarketBeat.com...
MarketBeat·28d ago
News Placeholder
Needham & Company LLC Has Lowered Expectations for Autolus Therapeutics (NASDAQ:AUTL) Stock Price
Needham & Company LLC lowered their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday...
MarketBeat·29d ago
News Placeholder
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell ShuttleTM Platform
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the...
Business Wire·1mo ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Shares Up 13.5% on Analyst Upgrade
Autolus Therapeutics (NASDAQ:AUTL) Trading Up 13.5% Following Analyst Upgrade...
MarketBeat·1mo ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Given New $11.00 Price Target at Needham & Company LLC
Needham & Company LLC upped their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Monday...
MarketBeat·1mo ago
News Placeholder
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 PR Newswire VANCOUVER, BC, Dec. 19...
PR Newswire·2mo ago
News Placeholder
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are covering the company, Marketbeat.com...
MarketBeat·2mo ago
<
1
2
...
>

Latest AUTL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.